VSTM
HealthcareVerastem, Inc.
$6.87
$-0.36 (-4.98%)
Jan 5, 2026
Price History (1Y)
Analysis
Verastem, Inc. is a healthcare company in the biotechnology sector with a market capitalization of $517.45M and 78 employees. The company's industry is characterized by a focus on research and development of new treatments. Financially, Verastem has reported significant losses, with a net income (TTM) of -$241,106,000 and an EBITDA of -$159,807,008. However, the company's gross margin stands at 85.1%, indicating some operational efficiency. Verastem's returns on equity (-2888.7%) and assets (-66.1%) are negative, suggesting significant financial strain. The company has $137.71M in cash reserves but also carries $89.48M in debt. The company's valuation metrics are mixed, with a forward P/E ratio of -4.12 and a price to book value of -29.48. Verastem's price to sales ratio is 38.68, indicating that investors may be willing to pay a premium for the company's shares. The beta of 0.44 suggests some correlation with the overall market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $517.45M
- P/E Ratio
- N/A
- 52-Week High
- $11.25
- 52-Week Low
- $4.01
- Avg Volume
- 2.27M
- Beta
- 0.44
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 78